Self-Assembled Nanoparticles of Diruthenium(II,III)-Ibuprofen Anticancer Metallodrug

Autor(es)

Marcio Hayashi ^[1] ; Samara R. Alves ^[2] ; Iguatinã M. Costa ^[3] ; Denise de Oliveira Silva ^[4]

Afiliação do(s) autor(es)

^[1] Universidade de São Paulo. Instituto de Química. Departamento de Química Fundamental - Brasil

^[2] Universidade de São Paulo. Instituto de Química. Departamento de Química Fundamental - Brasil

^[3] Universidade de São Paulo. Instituto de Química. Departamento de Química Fundamental - Brasil

^[4] Universidade de São Paulo. Instituto de Química. Departamento de Química Fundamental - Brasil

• Tipo de documento: Artigo Científico
• Fonte: Journal of the Brazilian Chemical Society; v. 31, n. 11, p. 2331-2341, 2020-10-30.

Resumo

The diruthenium(II,III)-ibuprofen (RuIbp) metallodrug shows anticancer activity in vitro and in vivo. The encapsulation into lipid nanoparticles enhanced the efficacy in glioblastoma, breast and prostate cancer cells. Here we report data for RuIbp hydrophobicity, solubility in alcohol/water, and behavior in 1-5% ethanol/water and ethanol/cell culture medium. RuIbp is capable of spontaneously generate self-assembled RuIbpNP nanoparticles when drug ethanolic solutions are added to water or cell growth culture medium at 1-5% ethanol. The phenomenon was investigated, and the nanoparticles characterized. RuIbpNP nanoparticles formed at 100-200 µmol L−1 RuIbp are colloidally stable and nearly spherical showing zeta potential about +40 mV and particle size about 100 (aqueous suspension) and 180 nm (culture medium). The integrity of the [Ru2(Ibp)4] framework was confirmed by spectroscopy and mass spectrometry. Significant amount of metallodrug was found in suspension (85%, culture medium; 54%, culture medium with cells). The uptake by U87MG glioblastoma cells was 6% at 24 h. The spontaneous nanosizing of RuIbp in the form of nanosuspensions may explain the biological activity of this highly hydrophobic metallodrug. The present findings expand the knowledge on the behavior of RuIbp, opening new directions to exploit the properties of the metallodrug targeting cancer therapy. (AU)

• Processo FAPESP: 14/23481-7 - Estudo de nanopartículas baseadas em lipídios como carregadores de metalofármacos de rutênio com atividade anticâncer
• Beneficiário: Samara Rodrigues Alves
• Modalidade de apoio: Bolsas no Brasil - Doutorado Direto
• Processo FAPESP: 14/23047-5 - Metalofármacos anticancerígenos de rutênio com ligantes bioativos: síntese, interação com biomoléculas e preparação de sistemas biocompatíveis nanoparticulados para carregamento e liberação
• Beneficiário: Denise de Oliveira Silva
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 16/23028-6 - Estudo do comportamento químico de metalofármacos de dirutênio(II,III) contendo anti-inflamatórios
• Beneficiário: Marcio Hayashi
• Modalidade de apoio: Bolsas no Brasil - Iniciação Científica